It was announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines, have announced a partnership agreement worth up to US$ 34 million for the ongoing development of The RNA Printer prototype—a transportable, down-scaled, automated messenger RNA (mRNA) printing facility. This innovative platform will provide a rapid supply of lipid-nanoparticle (LNP)-formulated mRNA vaccine candidates that can target known pathogens (including Lassa Fever, Yellow Fever, and Rabies) and prepare for rapid response to new and previously unknown pathogens (referred to by WHO as “Disease X”).
Rapiscan® Systems, a leading global supplier of security inspection technologies, has announced the launch of its new, high-performance ORION™ series product line.
DHHS released various information on CHEMM for Fourth Generation Agents. All this information here
After the incidents in the United Kingdom (U.K.) in 2018 involving a fourth generation agent, the White House National Security Council convened
Written by Zoe Rutherford on Friday, 15 March 2019
Written by Zoe Rutherford on Friday, 01 March 2019
Written by Zoe Rutherford on Thursday, 28 February 2019
Written by Gwyn Winfield on Thursday, 28 February 2019
Written by Zoe Rutherford on Wednesday, 27 February 2019